InMed Pharmaceuticals Inc

NASDAQ:INM  
5.57
-1.35 (-19.51%)
Layoffs, Earnings Announcements

Inmed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results And Provides Business Update

Published: 09/23/2022 16:37 GMT
InMed Pharmaceuticals Inc (INM) - Inmed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update.
Inmed Pharmaceuticals Inc FY Loss per Share $33.17.
Inmed Pharmaceuticals- in H2 Fiscal 2022 Inmed and Its Baymedica Unit Implemented Significant Cost Saving Measures, Including Some Personnel Changes.
Inmed Pharmaceuticals Inc- Initiatives Included a Reduction in Total Headcount and Voluntary Salary Reductions for Several Members of Management.
Inmed Pharmaceuticals Inc- Changes Have Resulted in a Reduction by Approximately 25% of Current Workforce.
Inmed Pharmaceuticals- Headcount Cuts, Cost Reduction Initiatives, Expected to Result in Human Resource Expense Savings of About 30% on Annualized Basis.
Inmed Pharmaceuticals Inc- Inmed President and CEO Eric A. Adams Volunteered a 28% Reduction in Salary As Compared to Previous Year.
Inmed Pharmaceuticals Inc- As Part of Expense Reduction Initiatives, No Employee Received an Annual Performance Bonus for Fiscal Year 2022.
Revenue is expected to be $0.6 Million
Adjusted EPS is expected to be -$6.25

Next Quarter Revenue Guidance is expected to be $0.75 Million
Next Quarter EPS Guidance is expected to be -$5.50

More details on our Analysts Page.